Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holman, R. R.
Right arrow Articles by Turner, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holman, R. R.
Right arrow Articles by Turner, R. C.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 22, Issue 6 960-964, Copyright © 1999 by American Diabetes Association

ARTICLES

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

RR Holman, CA Cull and RC Turner
Diabetes Research Laboratories, University of Oxford, Radcliffe Infirmary, U.K.

OBJECTIVE: To determine the degree to which alpha-glucosidase inhibitors, with their unique mode of action primarily reducing postprandial hyperglycemia, offer an additional therapeutic approach in the long-term treatment of type 2 diabetes. RESEARCH DESIGN AND METHODS: We studied 1,946 patients (63% men) who were previously enrolled in the U.K. Prospective Diabetes Study (UKPDS). The patients were randomized to acarbose (n = 973), titrating to a maximum dose of 100 mg three times per day, or to matching placebo (n = 973). Mean +/- SD age was 59 +/- 9 years, body weight 84 +/- 17 kg, diabetes duration 7.6 +/- 2.9 years, median (interquartile range) HbA1c 7.9% (6.7-9.5), and fasting plasma glucose (FPG) 8.7 mmol/l (6.8-11.1). Fourteen percent of patients were treated with diet alone, 52% with monotherapy, and 34% with combined therapy. Patients were monitored in UKPDS clinics every 4 months for 3 years. The main outcome measures were HbA1c, FPG, body weight, compliance with study medication, incidence of side effects, and frequency of major clinical events. RESULTS: At 3 years, a lower proportion of patients were taking acarbose compared with placebo (39 vs. 58%, P < 0.0001), the main reasons for noncompliance being flatulence (30 vs. 12%, P < 0.0001) and diarrhea (16 vs. 8%, P < 0.05). Analysis by intention to treat showed that patients allocated to acarbose, compared with placebo, had 0.2% significantly lower median HbA1c at 3 years (P < 0.001). In patients remaining on their allocated therapy, the HbA1c difference at 3 years (309 acarbose, 470 placebo) was 0.5% lower median HbA1c (8.1 vs. 8.6%, P < 0.0001). Acarbose appeared to be equally efficacious when given in addition to diet alone; in addition to monotherapy with a sulfonylurea, metformin, or insulin; or in combination with more complex treatment regimens. No significant differences were seen in FPG, body weight, incidence of hypoglycemia, or frequency of major clinical events. CONCLUSIONS: Acarbose significantly improved glycemic control over 3 years in patients with established type 2 diabetes, irrespective of concomitant therapy for diabetes. Careful titration of acarbose is needed in view of the increased noncompliance rate seen secondary to the known side effects.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Exploring Treatment Strategies for Type 2 Diabetes
Diabetes Care, October 1, 2007; 30(10): 2737 - 2745.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S.-H. Hsiao, L.-H. Liao, P.-N. Cheng, and T.-J. Wu
Hepatotoxicity Associated with Acarbose Therapy
Ann. Pharmacother., January 1, 2006; 40(1): 151 - 154.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
W. L Isley
Review: {alpha} glucosidase inhibitors improve glycaemic control but have uncertain effects on patient-important outcomes in type 2 diabetes
Evid. Based Med., December 1, 2005; 10(6): 174 - 174.
[Full Text] [PDF]

Home page
 Clin. DiabetesHome page
B. Kimmel and S. E. Inzucchi
Oral Agents for Type 2 Diabetes: An Update
Clin. Diabetes, April 1, 2005; 23(2): 64 - 76.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. Mino-Leon, A. Figueras, D. Amato, and J.-R. Laporte
Treatment of Type 2 Diabetes in Primary Health Care: A Drug Utilization Study
Ann. Pharmacother., March 1, 2005; 39(3): 441 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. J. Abrahamson
Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context
Arch Intern Med, March 8, 2004; 164(5): 486 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Ludvik, B. Neuffer, and G. Pacini
Efficacy of Ipomoea batatas (Caiapo) on Diabetes Control in Type 2 Diabetic Subjects Treated With Diet
Diabetes Care, February 1, 2004; 27(2): 436 - 440.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Brand-Miller, S. Hayne, P. Petocz, and S. Colagiuri
Low-Glycemic Index Diets in the Management of Diabetes: A meta-analysis of randomized controlled trials
Diabetes Care, August 1, 2003; 26(8): 2261 - 2267.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M. Fisher
Prevention of macrovascular complications
Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B21 - B26.
[Abstract] [PDF]

Home page
 JAMAHome page
J. M. Poothullil, N. Mikhail, and S. E. Inzucchi
Drug Therapy for Patients With Type 2 Diabetes
JAMA, April 3, 2002; 287(13): 1645 - 1646.
[Full Text] [PDF]

Home page
 JAMAHome page
S. E. Inzucchi
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
JAMA, January 16, 2002; 287(3): 360 - 372.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. P. Erlinger and F. L. Brancati
Postchallenge Hyperglycemia in a National Sample of U.S. Adults With Type 2 Diabetes
Diabetes Care, October 1, 2001; 24(10): 1734 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
H. Fujita, T. Yamagami, and K. Ohshima
Long-Term Ingestion of a Fermented Soybean-Derived Touchi-Extract with {alpha}-Glucosidase Inhibitory Activity Is Safe and Effective in Humans with Borderline and Mild Type-2 Diabetes
J. Nutr., August 1, 2001; 131(8): 2105 - 2108.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. M. Gribble, S. E. Manley, and J. C. Levy
Randomized Dose Ranging Study of the Reduction of Fasting and Postprandial Glucose in Type 2 Diabetes by Nateglinide (A-4166)
Diabetes Care, July 1, 2001; 24(7): 1221 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
V. S. Catalan, J. A. Couture, and J. LeLorier
Predictors of Persistence of Use of the Novel Antidiabetic Agent Acarbose
Arch Intern Med, April 23, 2001; 161(8): 1106 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
H. Fujita, T. Yamagami, and K. Ohshima
Fermented Soybean-Derived Water-Soluble Touchi Extract Inhibits {{alpha}}-Glucosidase and Is Antiglycemic in Rats and Humans after Single Oral Treatments
J. Nutr., April 1, 2001; 131(4): 1211 - 1213.
[Abstract] [Full Text]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. C Levy
Review: UKPDS odyssey -- 2001
The British Journal of Diabetes & Vascular Disease, January 1, 2001; 1(1): 14 - 21.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring
Pathophysiology and Pharmacological Treatment of Insulin Resistance
Endocr. Rev., December 1, 2000; 21(6): 585 - 618.
[Abstract] [Full Text]

Home page
 DTBHome page
Reducing long-term complications of type 2 diabetes
DTB, November 1, 1999; 37(11): 84 - 87.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.